Prime Medicine, Inc. (PRME)
PRMENASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$4.32
+0.4300 (+11.05%) today
Regular session, Nov 13, 11:55 AM ET
- Market cap
- $785.92m
- P/E
- –
- EPS, last 4 quarters
- $-0.9600
- Dividend yield
- –
- Day range
- $4.01 to $4.36
- 52-week range
- $2.67 to $5.91
- Average volume
- –
- Previous close
- $3.89
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $8.20, +89.8% from here
Earnings
next estimate $-0.2400Next report
Dec 2025
+12.0%
Mar 2026
-16.7%
Jun 2026
0.0%
Sep 2026
+4.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.23m | $838.0k | $856.0k | $1.15m |
| Gross profit | $1.23m | $838.0k | $856.0k | $1.15m |
| Operating income | -$53.97m | -$48.61m | -$50.65m | -$43.28m |
| Net income | -$50.58m | -$46.08m | -$49.12m | -$42.11m |
Last four quarters: revenue $4.07m, margin -4613.1%, free cash flow -$156.85m
News
8 latest- $PRME stock is up 16% today. Here's what we see in our data.Quiver Quantitative · Jul 21, 2025
- Prime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis TreatmentQuiver Quantitative · Jul 16, 2025
- $PRME stock is up 12% today. Here's what we see in our data.Quiver Quantitative · Jul 9, 2025
- $PRME stock is up 20% today. Here's what we see in our data.Quiver Quantitative · Jul 2, 2025
- $PRME stock is up 13% today. Here's what we see in our data.Quiver Quantitative · Jun 17, 2025
- Insider Purchase: 10% owner at $PRME Buys 21,000 SharesQuiver Quantitative · Jun 12, 2025
- $PRME stock is up 7% today. Here's what we see in our data.Quiver Quantitative · Jun 5, 2025
- Prime Medicine, Inc. Announces Positive Phase 1/2 Data for PM359 and Strategic Restructuring Focused on Liver Disease ProgramsQuiver Quantitative · May 19, 2025
The company
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing's versatile gene editing capabilities could unlock opportunities across thousands of potential indications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- primemedicine.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.